Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
Ann Intern Med
    July 2024
  1. TANG H, Lu Y, Donahoo WT, Shao H, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/M24-0329.
    >> Share


  2. Summary for Patients: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/P24-0004.
    >> Share

  3. CENTOR RM, Crandall CJ
    Annals On Call - ACP Recommendation: Pharmacologic Treatment of Type 2 Diabetes.
    Ann Intern Med. 2024;177:e2401521OC.
    >> Share

  4. TANNER M
    In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortality.
    Ann Intern Med. 2024;177:JC83.
    >> Share

  5. CHIU YH, Huybrechts KF, Patorno E, Yland JJ, et al
    Metformin Use in the First Trimester of Pregnancy and Risk for Nonlive Birth and Congenital Malformations: Emulating a Target Trial Using Real-World Data.
    Ann Intern Med. 2024;177:862-870.
    >> Share

    June 2024
  6. CRAWFORD AL, Laiteerapong N
    Type 2 Diabetes.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/AITC202406180.
    >> Share

  7. SMETANA GW, Romeo GR, Rosas SE, Burns RB, et al
    How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/M24-0764.
    >> Share

    May 2024
  8. LAINE C, Moyer DV, Qaseem A
    Newer Pharmacologic Treatments for Type 2 Diabetes.
    Ann Intern Med. 2024 May 28. doi: 10.7326/ANNALS-24-00698.
    >> Share

  9. O'BRIEN C, Dinneen SF
    In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0028.
    >> Share

  10. BATES ER
    In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026.
    >> Share

  11. MARUTHUR NM, Pilla SJ, White K, Wu B, et al
    Effect of Isocaloric, Time-Restricted Eating on Body Weight in Adults With Obesity : A Randomized Controlled Trial.
    Ann Intern Med. 2024;177:549-558.
    >> Share

    April 2024
  12. YEN FS, Hwu CM, Liu JS, Wu YL, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Ann Intern Med. 2024 Apr 30. doi: 10.7326/M23-1874.
    >> Share

  13. DRAKE T, Landsteiner A, Langsetmo L, MacDonald R, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1490.
    >> Share

  14. SCHOUSBOE JT, Landsteiner A, Drake T, Sultan S, et al
    Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1492.
    >> Share

  15. QASEEM A, Obley AJ, Shamliyan T, Hicks LA, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-2788.
    >> Share

  16. SYED FZ
    Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M24-0861.
    >> Share


  17. Annals Video Summary - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Apr 19:eM231554. doi: 10.7326/M23-1554.
    >> Share


  18. Visual Guideline - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Visual Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19:eM240803. doi: 10.7326/M24-0803.
    >> Share

  19. KELSEY M, Newby LK
    In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.
    Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0016.
    >> Share

  20. HWANG JH, Hsu CY
    In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.
    Ann Intern Med. 2024;177:JC40.
    >> Share

  21. EGAN AM
    In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin.
    Ann Intern Med. 2024;177:JC47.
    >> Share

    March 2024
  22. GARABEDIAN LF, Zhang F, Costa R, Argetsinger S, et al
    Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
    Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-1965.
    >> Share

  23. KOUTROUMPAKIS E, Deswal A
    In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
    Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0008.
    >> Share

  24. PERSELL SD, Petito LC, Lee JY, Meeker D, et al
    Reducing Care Overuse in Older Patients Using Professional Norms and Accountability : A Cluster Randomized Controlled Trial.
    Ann Intern Med. 2024;177:324-334.
    >> Share

    February 2024
  25. PAPPACHAN JM
    In T2DM with obesity, time-restricted eating increased weight loss and reduced HbA(1c) level at 6 mo.
    Ann Intern Med. 2024;177:JC16.
    >> Share

    January 2024
  26. CASEY C, Dinneen SF
    In latent autoimmune diabetes in adults, mortality was similar to T2DM but retinopathy was higher at 5.9 y.
    Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0107.
    >> Share

  27. WEITZ HH, Merli GJ
    Annals Consult Guys - Postoperative Euglycemic Diabetic Ketoacidosis.
    Ann Intern Med. 2024;177:eW230012.
    >> Share

  28. LIAKOS A, Karagiannis T, Tsapas A
    In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA(1c) vs. daily basal insulin analogues at 52 wk.
    Ann Intern Med. 2024;177:JC6.
    >> Share

    December 2023
  29. CENTOR RM, Fang M
    Annals On Call - Type 1 Diabetes: Age at Diagnosis.
    Ann Intern Med. 2023 Dec 5:eA220023. doi: 10.7326/A22-0023.
    >> Share

  30. AGARWAL R, Tu W, Farjat AE, Farag YMK, et al
    Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
    Ann Intern Med. 2023 Dec 5. doi: 10.7326/M23-1023.
    >> Share

    November 2023
  31. LIU M, Aggarwal R, Zheng Z, Yeh RW, et al
    Cardiovascular Health of Middle-Aged U.S. Adults by Income Level, 1999 to March 2020 : A Serial Cross-Sectional Study.
    Ann Intern Med. 2023 Nov 21. doi: 10.7326/M23-2109.
    >> Share


  32. Correction: Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes.
    Ann Intern Med. 2023 Nov 7. doi: 10.7326/L23-0410.
    >> Share

  33. DAVIDSON MB
    In adults with BMI >/=27 kg/m(2) and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
    Ann Intern Med. 2023 Nov 7. doi: 10.7326/J23-0089.
    >> Share

  34. NABRDALIK K, Lip GYH
    In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes.
    Ann Intern Med. 2023 Nov 7. doi: 10.7326/J23-0081.
    >> Share

    October 2023
  35. LAU D
    In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
    Ann Intern Med. 2023 Oct 3. doi: 10.7326/J23-0077.
    >> Share

  36. BELAL H, Gandhi GY
    In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA(1c) vs. daily glargine at 52 wk.
    Ann Intern Med. 2023;176:JC113.
    >> Share

  37. BELAL H, Gandhi GY
    In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA(1c) vs. daily degludec at 26 wk.
    Ann Intern Med. 2023;176:JC112.
    >> Share

    September 2023
  38. FANG M, Wang D, Echouffo-Tcheugui JB, Selvin E, et al
    Age at Diagnosis in U.S. Adults With Type 1 Diabetes.
    Ann Intern Med. 2023 Sep 26. doi: 10.7326/M23-1707.
    >> Share

  39. BAJAJ HS, Aberle J, Davies M, Donatsky AM, et al
    Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial.
    Ann Intern Med. 2023 Sep 26. doi: 10.7326/M23-1288.
    >> Share

  40. KIANERSI S, Liu Y, Guasch-Ferre M, Redline S, et al
    Chronotype, Unhealthy Lifestyle, and Diabetes Risk in Middle-Aged U.S. Women : A Prospective Cohort Study.
    Ann Intern Med. 2023 Sep 12. doi: 10.7326/M23-0728.
    >> Share

  41. LIN K, Song M, Giovannucci E
    Evening Chronotype, Circadian Misalignment, and Metabolic Health: Implications for Diabetes Prevention and Beyond.
    Ann Intern Med. 2023 Sep 12. doi: 10.7326/M23-2257.
    >> Share

  42. FANG M, Echouffo-Tcheugui JB, Selvin E
    Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.
    Ann Intern Med. 2023;176:eL230228.
    >> Share

  43. POPOVIC D, Patoulias D, Papanas N
    Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.
    Ann Intern Med. 2023;176:eL230227.
    >> Share

    August 2023
  44. ZHONG VW, Yu D, Zhao L, Yang Y, et al
    Achievement of Guideline-Recommended Targets in Diabetes Care in China : A Nationwide Cross-Sectional Study.
    Ann Intern Med. 2023 Aug 1. doi: 10.7326/M23-0442.
    >> Share

  45. HANDS JM, Patrick R, Frame LA
    Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes.
    Ann Intern Med. 2023;176:eL230201.
    >> Share

  46. PITTAS AG, Kawahara T, Jorde R, Dawson-Hughes B, et al
    Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes.
    Ann Intern Med. 2023;176:eL230202.
    >> Share

  47. BELAL H, Gandhi GY
    In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA(1c) at 26 wk.
    Ann Intern Med. 2023;176:JC94.
    >> Share

    July 2023
  48. MCCORMICK N, Yokose C, Wei J, Lu N, et al
    Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
    Ann Intern Med. 2023 Jul 25. doi: 10.7326/M23-0724.
    >> Share


  49. Correction: Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Ann Intern Med. 2023 Jul 18. doi: 10.7326/L23-0249.
    >> Share

  50. LOCKHART MJ, Dinneen SF
    In type 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA(1c) at 26 wk.
    Ann Intern Med. 2023 Jul 4. doi: 10.7326/J23-0046.
    >> Share

  51. LOCKHART MJ, Dinneen SF
    In type 1 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA(1c) at 26 wk.
    Ann Intern Med. 2023 Jul 4. doi: 10.7326/J23-0045.
    >> Share

  52. PATOULIAS D
    Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
    Ann Intern Med. 2023;176:eL230069.
    >> Share

  53. SCHECHTER M, Chertow GM, Heerspink HJL
    Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
    Ann Intern Med. 2023;176:eL230070.
    >> Share

    June 2023
  54. SLOAN CE, Campagna A, Tu K, Doerstling S, et al
    Online Crowdfunding Campaigns for Diabetes-Related Expenses.
    Ann Intern Med. 2023 Jun 13. doi: 10.7326/M23-0540.
    >> Share

    May 2023
  55. NISSEN SE
    Comparative Effectiveness of Diabetes Drugs: The Use and Misuse of Observational Research.
    Ann Intern Med. 2023 May 9. doi: 10.7326/M23-0958.
    >> Share

  56. RICHARDSON TL JR, Halvorson AE, Hackstadt AJ, Hung AM, et al
    Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Ann Intern Med. 2023 May 9. doi: 10.7326/M22-2751.
    >> Share

  57. VAN NORMAN M, Molony DA
    KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD.
    Ann Intern Med. 2023 May 2. doi: 10.7326/J23-0023.
    >> Share

  58. LAU D
    In prediabetes, oral vitamin D reduces progression to new-onset diabetes.
    Ann Intern Med. 2023 May 2. doi: 10.7326/J23-0030.
    >> Share

    April 2023
  59. HANNA C, Pettersen K, Pedley N
    First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Ann Intern Med. 2023;176:eL230006.
    >> Share

  60. ADIE SK, Konerman MC
    Annals for Hospitalists Inpatient Notes - Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction-What Hospitalists Need to Know.
    Ann Intern Med. 2023;176:eM230588.
    >> Share

  61. LAITEERAPONG N, Alexander J, Philipson L, Winn AN, et al
    First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Ann Intern Med. 2023;176:eL230007.
    >> Share

  62. CARRIAZO S, Ortiz A, Fernandez-Fernandez B
    First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Ann Intern Med. 2023;176:eL230005.
    >> Share

  63. TANG S, Shao H, Ali MK, Zhang P, et al
    Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample.
    Ann Intern Med. 2023;176:582-583.
    >> Share

    March 2023
  64. PATEL T
    SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes.
    Ann Intern Med. 2023 Mar 7. doi: 10.7326/J23-0002.
    >> Share

  65. KWONG YD, Hsu CY
    In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y.
    Ann Intern Med. 2023;176:JC26.
    >> Share

    February 2023
  66. FANG M, Jeon Y, Echouffo-Tcheugui JB, Selvin E, et al
    Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.
    Ann Intern Med. 2023 Feb 14. doi: 10.7326/M22-3078.
    >> Share


  67. Summary for Patients: Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes.
    Ann Intern Med. 2023 Feb 7. doi: 10.7326/P22-0031.
    >> Share

  68. MCKENNA MJ, Flynn MAT
    Preventing Type 2 Diabetes With Vitamin D: Therapy Versus Supplementation.
    Ann Intern Med. 2023 Feb 7. doi: 10.7326/M23-0220.
    >> Share

  69. PITTAS AG, Kawahara T, Jorde R, Dawson-Hughes B, et al
    Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials.
    Ann Intern Med. 2023 Feb 7. doi: 10.7326/M22-3018.
    >> Share


  70. Annals Video Summary - Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes.
    Ann Intern Med. 2023 Feb 7:eM223698. doi: 10.7326/M22-3698.
    >> Share

  71. CENTOR RM, Laiteerapong N, Winn AN
    Annals On Call - First-Line Drug Therapy for Type 2 Diabetes.
    Ann Intern Med. 2023;176:eA220004.
    >> Share

    January 2023

  72. Correction: 2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease.
    Ann Intern Med. 2023 Jan 17. doi: 10.7326/L23-0010.
    >> Share

  73. NAVANEETHAN SD, Zoungas S, Caramori ML, Chan JCN, et al
    Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.
    Ann Intern Med. 2023 Jan 10. doi: 10.7326/M22-2904.
    >> Share

  74. SAUNDERS M, Laiteerapong N
    2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease: An Important First Step, More Work to Do.
    Ann Intern Med. 2023 Jan 10. doi: 10.7326/M22-3635.
    >> Share

  75. BROWN K, Donato AA
    In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
    Ann Intern Med. 2023 Jan 3. doi: 10.7326/J22-0105.
    >> Share

  76. BROWN K, Donato AA
    In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
    Ann Intern Med. 2023 Jan 3. doi: 10.7326/J22-0104.
    >> Share

  77. GREENBLATT LH
    In type 2 diabetes, the BT-001 smartphone app reduced HbA(1c) more than a control app at 90 d.
    Ann Intern Med. 2023 Jan 3. doi: 10.7326/J22-0109.
    >> Share

  78. LOCKHART M, Dinneen SF
    In T1DM, open-source automated insulin delivery increased glucose time in target vs. sensor-augmented pumps.
    Ann Intern Med. 2023;176:JC11.
    >> Share

    December 2022

  79. Summary for Patients: Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/P22-0022.
    >> Share

  80. HANSEN CD, Gram-Kampmann EM, Hansen JK, Hugger MB, et al
    Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-1787.
    >> Share

  81. CARR JC
    BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/J22-0093.
    >> Share

  82. SHI X, He J, Lin M, Liu C, et al
    Comparative Effectiveness of Team-Based Care With and Without Clinical Decision Support System for Diabetes Management : A Cluster Randomized Trial.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/M22-1950.
    >> Share


  83. Summary for Patients: Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/P22-0020.
    >> Share

  84. SCHECHTER M, Jongs N, Chertow GM, Mosenzon O, et al
    Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/M22-2115.
    >> Share

  85. SHIN H, Schneeweiss S, Glynn RJ, Patorno E, et al
    Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.
    Ann Intern Med. 2022;175:W155.
    >> Share

  86. QIU M
    Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.
    Ann Intern Med. 2022;175:W155.
    >> Share

    October 2022
  87. FUDIM M, Van Spall HGC
    In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status.
    Ann Intern Med. 2022 Oct 4. doi: 10.7326/J22-0075.
    >> Share

  88. CHOI JG, Winn AN, Skandari MR, Franco MI, et al
    First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
    Ann Intern Med. 2022 Oct 4. doi: 10.7326/M21-2941.
    >> Share

  89. DAVIDSON MB
    In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
    Ann Intern Med. 2022 Oct 4. doi: 10.7326/J22-0072.
    >> Share

    September 2022
  90. RACHMASARI K, Montori VM
    In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia.
    Ann Intern Med. 2022 Sep 6. doi: 10.7326/J22-0063.
    >> Share

    August 2022
  91. MONTORI VM
    Patients surviving COVID-19 had increased risk for incident diabetes vs. persons without COVID-19.
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0052.
    >> Share

  92. TANNER M
    In diabetes, some statins reduce non-HDL-C better than others vs. placebo.
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0051.
    >> Share

  93. BROPHY JM
    In HF, SGLT2 inhibitors reduce HF hospitalizations at up to 2 y.
    Ann Intern Med. 2022;175:JC87.
    >> Share

    June 2022
  94. BUTT JH, Dewan P, Merkely B, Belohlavek J, et al
    Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
    Ann Intern Med. 2022;175:820-830.
    >> Share

  95. ZOU X, Shi Q, Vandvik PO, Guyatt G, et al
    Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure : A Systematic Review and Meta-analysis.
    Ann Intern Med. 2022;175:851-861.
    >> Share

    May 2022
  96. SHIN H, Schneeweiss S, Glynn RJ, Patorno E, et al
    Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
    Ann Intern Med. 2022 May 24. doi: 10.7326/M21-4012.
    >> Share

  97. NGO-METZGER Q
    Diabetes Screening: Different Thresholds for Different Racial/Ethnic Groups.
    Ann Intern Med. 2022 May 10. doi: 10.7326/M22-1235.
    >> Share

  98. AGGARWAL R, Bibbins-Domingo K, Yeh RW, Song Y, et al
    Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds.
    Ann Intern Med. 2022 May 10. doi: 10.7326/M20-8079.
    >> Share


  99. Summary for Patients: Screening for Diabetes by Race and Ethnicity in the United States.
    Ann Intern Med. 2022 May 10. doi: 10.7326/P22-0008.
    >> Share

  100. KAUFFMAN RP
    In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0023.
    >> Share

  101. MAYNE KJ, Herrington WG
    In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0029.
    >> Share

  102. CENTOR RM, Syed FZ
    Annals On Call - Type 1 Diabetes Mellitus in Adults.
    Ann Intern Med. 2022 May 3:OC1. doi: 10.7326/A21-0010.
    >> Share

  103. WENSINK MJ, Lu Y, Tian L, Shaw GM, et al
    Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring : A Nationwide Cohort Study.
    Ann Intern Med. 2022;175:665-673.
    >> Share

    April 2022
  104. TANNER M
    Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive class.
    Ann Intern Med. 2022 Apr 5. doi: 10.7326/J22-0018.
    >> Share

    March 2022
  105. LOUIS GMB
    Paternal Preconception Diabetes Drugs and Birth Defects in Offspring: A Call for More Conclusive Study.
    Ann Intern Med. 2022 Mar 29. doi: 10.7326/M22-0770.
    >> Share

  106. SYED FZ
    Type 1 Diabetes Mellitus.
    Ann Intern Med. 2022 Mar 8. doi: 10.7326/AITC202203150.
    >> Share

  107. SINGH M
    In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0009.
    >> Share

  108. KELSEY MD, Newby LK
    In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.
    Ann Intern Med. 2022;175:JC26.
    >> Share

  109. PRETE A, Subramanian A, Bancos I, Chortis V, et al
    Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study.
    Ann Intern Med. 2022;175:325-334.
    >> Share

    February 2022
  110. HUANG HK, Liu PP, Lin SM, Hsu JY, et al
    Diabetes-Related Complications and Mortality in Patients With Atrial Fibrillation Receiving Different Oral Anticoagulants : A Nationwide Analysis.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-3498.
    >> Share


  111. The National Clinical Care Commission Report: Improving Federal Programs That Impact Diabetes Prevention and Care.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-4175.
    >> Share

    January 2022
  112. PATORNO E, Htoo PT, Everett BM, Kim SC, et al
    Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Ann Intern Med. 2022;175:W4.
    >> Share

  113. PATORNO E, Htoo PT, Glynn RJ, Schneeweiss S, et al
    Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Ann Intern Med. 2022;175:W4-W5.
    >> Share

  114. BEPO L, Makam AN, Nguyen OK
    Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Ann Intern Med. 2022;175:W3.
    >> Share

  115. QIU M
    Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Ann Intern Med. 2022;175:W3-W4.
    >> Share

    November 2021

  116. Summary for Patients: Do Gastric Bypass and Sleeve Gastrectomy Help Reduce Liver Fat Content and Scarring in Patients With Type 2 Diabetes?
    Ann Intern Med. 2021 Nov 30. doi: 10.7326/P21-0012.
    >> Share

  117. SEEBERG KA, Borgeraas H, Hofso D, Smastuen MC, et al
    Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis : A Randomized Controlled Trial.
    Ann Intern Med. 2021 Nov 30. doi: 10.7326/M21-1962.
    >> Share

  118. GANDHI GY
    In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    >> Share

    October 2021
  119. OLSON DE
    In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control.
    Ann Intern Med. 2021 Oct 5. doi: 10.7326/ACPJ202110190.
    >> Share

  120. JENKINS I
    Medical Violence.
    Ann Intern Med. 2021;174:1472-1473.
    >> Share

    September 2021
  121. PATORNO E, Htoo PT, Glynn RJ, Schneeweiss S, et al
    Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Ann Intern Med. 2021 Sep 28. doi: 10.7326/M21-0893.
    >> Share

  122. BOGGILD MK, Cheung AM
    Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM.
    Ann Intern Med. 2021;174:JC106.
    >> Share

    June 2021
  123. GANDRA S, Ram S, Levitz SM
    The "Black Fungus" in India: The Emerging Syndemic of COVID-19-Associated Mucormycosis.
    Ann Intern Med. 2021 Jun 8. doi: 10.7326/M21-2354.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016